Trials / Completed

CompletedNCT04773756

Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt

Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt (Single Center Study)

Status: Completed
Phase: Phase 4
Study type: Interventional
Enrollment: 54 (actual)

Sponsor: Alexandria University · Academic / Other
Sex: All
Age: 12 Years – 90 Years
Healthy volunteers: Not accepted

Summary

Sofosbuvir has been recently recommended as a possible antiviral for COVID-19, based on structural studies and multiple alignment analysis. By comparing the positive-stranded RNA genomes of HCV and SARS-CoV-2, it has been postulated that sofosbuvir might be an optimal nucleotide analogue to repurpose for COVID-19 treatment

Conditions

Covid19

Interventions

Type	Name	Description
DRUG	Sofosbuvir 400 MG/ Daclatasvir 60mg	Giving these two drugs for treatment of COVID patients

Timeline

Start date: 2020-11-01
Primary completion: 2020-11-30
Completion: 2020-12-12
First posted: 2021-02-26
Last updated: 2021-02-26

Locations

1 site across 1 country: Egypt

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT04773756. Inclusion in this directory is not an endorsement.